Full-Time

Accounts Payable Operations Specialist

Finance Operations

Posted on 9/23/2025

Collegium Pharmaceutical

Collegium Pharmaceutical

501-1,000 employees

Specialty biopharmaceuticals developing extended-release pain medications

Compensation Overview

$71.5k - $83k/yr

Canton, MA, USA

Hybrid

Required to be onsite in Stoughton, MA on Tuesday, Wednesday, and Thursday.

Category
Finance & Banking (1)
Required Skills
NetSuite
Word/Pages/Docs
Data Analysis
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • Bachelor’s degree or equivalent work experience required
  • Strong analytical, problem-solving, and communication skills
  • Proficiency with Microsoft Office (Excel, Outlook, PowerPoint, Word) and willingness to learn new technologies required
  • Strong attention to detail, organization, time management, and the ability to handle multiple tasks
Responsibilities
  • Process invoices for review, approval and timely payment using Netsuite
  • Review invoices and ensure accurate general ledger coding collaborating with business partners as necessary
  • Onboard new vendors and maintain vendor records to ensure accurate payment details
  • Respond to vendor inquiries and maintain positive vendor relationships
  • Train new users (bill approvers) in Netsuite
  • Lead weekly Accounts Payable meetings providing status updates and visibility into identified issues
  • Work with other Finance Team members and business partners to resolve issues and support cross-functional processes including monthly close and ad hoc projects
  • Continuously evaluate and propose enhancements to the AP process to streamline workflows and improve efficiency
  • Maintenance and management of dedicated Accounts Payable email inbox
  • Provide support for the monthly expense reporting process, reviewing reports and supporting Concur users
Desired Qualifications
  • 1-2 years+ years of relevant experience preferred
  • Experience with NetSuite, Concur and AP automation preferred
Collegium Pharmaceutical

Collegium Pharmaceutical

View

Preparing summary...

Company Size

501-1,000

Company Stage

IPO

Headquarters

Cumberland, Maryland

Founded

2002

Simplify Jobs

Simplify's Take

What believers are saying

  • Jornay PM revenue rose 36% year over year in Q1 2026.
  • AZSTARYS extends patent-protected ADHD revenue into 2037.
  • Pain portfolio cash flow funds debt reduction and acquisitions.

What critics are saying

  • Jornay PM concentration leaves growth dependent on one ADHD brand.
  • AZSTARYS integration risks cannibalization, missed synergies, and execution slippage.
  • Opioid portfolio faces prescribing scrutiny, payer pressure, and abuse-liability concerns.

What makes Collegium Pharmaceutical unique

  • Collegium pairs responsible pain management with a growing ADHD franchise.
  • Jornay PM uses evening-dosed delayed-release methylphenidate.
  • AZSTARYS adds a complementary prodrug stimulant with extended exposure.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Collegium Pharmaceutical who can refer or advise you

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

0%

2 year growth

6%
Yahoo Finance
Mar 26th, 2026
Collegium Pharmaceutical shares drop 26.8% as Q4 guidance disappoints despite $205.4M revenue

Collegium Pharmaceutical reported Q4 revenues of $205.4 million, up 12.9% year-on-year, meeting analysts' expectations. However, the quarter delivered mixed results, with full-year revenue guidance beating expectations but earnings per share significantly missing estimates. The branded pharmaceuticals sector faces tailwinds from precision medicine advancements and AI adoption in drug development, but confronts challenges including regulatory scrutiny, pricing pressures and patent cliffs forcing competition from generics. CEO Vikram Karnani highlighted progress on strategic priorities, including growth for Jornay PM and maximising the pain portfolio. However, Collegium delivered the weakest full-year guidance amongst its peers. Shares have fallen 26.8% since the earnings report and currently trade at $33.51. The 10 branded pharmaceuticals stocks tracked reported mixed Q4 results, with revenues missing consensus estimates by 1.6% on average.

Yahoo Finance
Mar 25th, 2026
Collegium Pharmaceutical executive sells 50,000 shares worth $2M under pre-set plan

Scott Dreyer, Executive Vice President and Chief Commercial Officer of Collegium Pharmaceutical, sold 49,976 shares of common stock in open-market transactions on 3 March 2026, worth $2 million, according to an SEC Form 4 filing. The sale was executed under a Rule 10b5-1 trading plan established in September 2025, which allows executives to sell shares at predetermined times to avoid trading on inside information. The transaction represents 41% of Dreyer's direct holdings, substantially larger than his historical median sale of 15,387 shares. Following the transaction, Dreyer retains 71,770 shares held directly, valued at approximately $2.4 million. Collegium Pharmaceutical develops specialty pain management products including Xtampza ER and Nucynta ER/IR, with a market capitalisation of $1.1 billion.

Collegium Pharmaceutical
Mar 20th, 2026
Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory – Collegium Pharmaceutical Inc.

The Investor Relations website contains information about Collegium Pharmaceutical Inc.'s business for stockholders, potential investors, and financial analysts.

AllSci
Mar 19th, 2026
Collegium acquires ADHD drug Azstarys from Corium Therapeutics for USD 650m plus milestones.

Collegium acquires ADHD drug Azstarys from Corium Therapeutics for USD 650m plus milestones. March 19, 2026 Collegium Pharmaceutical, based in Stoughton, Massachusetts, announced a definitive agreement to acquire Azstarys from Corium Therapeutics Holdings for USD 650 million in cash at closing, with up to USD 135 million in additional milestone payments tied to commercial and regulatory targets. The Collegium Azstarys acquisition covers a marketed central nervous system stimulant indicated for attention deficit hyperactivity disorder in patients aged six and older. Corium Therapeutics, a privately held company headquartered in Cambridge, Massachusetts, markets and distributes the product through its subsidiaries. The transaction is expected to close in Q2 2026, subject to Hart-Scott-Rodino approval and other customary conditions (source). Azstarys is a fixed-dose combination capsule containing serdexmethylphenidate and dexmethylphenidate, representing a differentiated ADHD treatment combining both immediate-release and long-acting components. Serdexmethylphenidate is a prodrug of dexmethylphenidate. The dexmethylphenidate component provides the immediate-release onset, while the prodrug undergoes enzymatic conversion to deliver extended exposure. Both components act on dopamine and norepinephrine reuptake in the central nervous system. The product generated more than 760,000 prescriptions in 2025 and is expected to produce over USD 50 million in second-half 2026 pro forma net revenue. Six Orange Book-listed patents support the product, most of which do not expire until December 2037. Collegium will fund the upfront payment through existing cash on hand and USD 300 million from a delayed draw term loan that is part of a syndicated credit facility announced in December 2025. The term loan carries interest at the term Secured Overnight Financing Rate plus a spread of 2.75% to 3.75%, depending on the company's first lien net leverage ratio. At closing, the rate will be SOFR plus 3.25%. Collegium expects post-close net leverage of approximately two times estimated 2026 combined adjusted EBITDA. The company stated the transaction is expected to be immediately accretive to adjusted EBITDA. Annual run-rate synergies are projected to exceed USD 50 million within twelve months of closing. The Collegium ADHD portfolio already includes Jornay PM, a delayed-release and extended-release methylphenidate capsule designed for evening dosing. Adding Azstarys gives Collegium a second commercialized ADHD product with a different release profile and dosing schedule. Collegium has historically operated in responsible pain management and has been expanding into neuropsychiatry. The Azstarys Corium deal extends the patent-protected revenue horizon of the combined ADHD portfolio to 2037. The ADHD stimulant market includes multiple methylphenidate and amphetamine-based products across immediate-release, extended-release, and prodrug formulations. Competitors targeting the same pharmacological class include: - Vyvanse (lisdexamfetamine) - Takeda - approved, amphetamine prodrug - Concerta (methylphenidate ER) - Janssen - approved, osmotic-release formulation - Adhansia XR (methylphenidate ER) - Adamas Pharmaceuticals - approved, multilayer extended-release Your email address will not be published. Required fields are marked *

Endpoints News
Mar 19th, 2026
Collegium is acquiring Corium's approved ADHD drug for $650M.

Collegium is acquiring Corium's approved ADHD drug for $650M. Biotech correspondent. Collegium Pharmaceutical is beefing up its portfolio in ADHD with the acquisition of Corium's FDA-approved drug Azstarys. The $650 million upfront deal carries up to... Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

INACTIVE